版本:
中国

公司高管: 石藥集團有限公司 (1093.HK)

1093.HK ( 香港证券交易所 )

13.84HKD
11:13 BJT
涨跌 (%)

HK$-0.02 (-0.14%)
收盘
HK$13.86
开盘
HK$13.86
当日最高
HK$13.96
当日最低
HK$13.64
成交量
5,506,420
平均成交量
36,250,512
52 周最高
HK$26.75
52 周最低
HK$9.90

概要

姓名 年龄 时间 职务

Cai Dongchen

64 2010 Executive Chairman of the Board, Chief Executive Officer

Pan Weidong

48 2017 Executive Vice Chairman of the Board

Chak Kin Man

52 2005 Executive Director

Li Chunlei

41 2017 Executive Director

Lu Hua

46 2015 Executive Director

Wang Huaiyu

54 2010 Executive Director

Qingxi Wang

52 2018 Executive Director

Wang Zhenguo

48 2012 Executive Director

Cuilong Zhang

50 2018 Executive Director

李 嘉士

58 Company Secretary, Non-Executive Director

Chan Siu Keung

60 2004 Independent Non-Executive Director

Chen Chuan

54 2016 Independent Non-Executive Director

Lo Yuk Lam

69 2014 Independent Non-Executive Director

王 波

58 2012 Independent Non-Executive Director

于 金明

60 2014 Independent Non-Executive Director

简历

姓名 描述

Cai Dongchen

Mr. Cai Dongchen is Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Cai is also the chairman of the Nomination Committee of the Company and a director of certain subsidiaries of the Group. Mr. Cai holds a MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry. Mr. Cai is a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”).

Pan Weidong

Mr. Weidong Pan is an Executive Vice Chairman of the Board of the Company. He was appointed as an executive director of the Company in 2006. Mr. Pan is also a director of certain subsidiaries of the Group. Mr. Pan holds an EMBA degree from Tsinghua University and has extensive experience in finance, accounting and investment.

Chak Kin Man

Mr. Chak Kin Man is Executive Director of the Company. Mr. Chak is also a director of certain subsidiaries of the Group. Mr. Chak is a certified public accountant of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Mr. Chak holds a bachelor of social sciences degree from The University of Hong Kong and has extensive experience in finance, accounting and investor relation.

Li Chunlei

Mr. Li Chunlei is Executive Director of the Company. Mr. Li is currently the Chief Scientist of the Group in charge of research and development. Mr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Mr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Mr. Li is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of approximately 20 nano drugs including “Duomeisu” (doxorubicin hydrochloride liposome injection) and paclitaxel albumin-bound nano particles.

Lu Hua

Mr. Lu Hua is Executive Director of the Company. Mr. Lu is also a director of certain subsidiaries of the Group. Mr. Lu holds a bachelor’s degree in science (chemistry) from Hebei Normal University, a master’s degree in engineering (pharmaceutical manufacturing) from Beijing University of Chemical Technology, an EMBA degree from Tsinghua University and a doctorate in engineering (pharmaceutical manufacturing) from Tianjin University. Mr. Lu has extensive experience in pharmaceutical engineering, production management and technical research.

Wang Huaiyu

Mr. Wang Huaiyu is Executive Director of the Company. He was appointed as an executive director of the Company in 2010. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in microbiology and biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

Qingxi Wang

Dr. Wang Qingxi serves as Executive Director of the Company. He joined the Group in 2013 and is currently a vice president of the R&D division and head of the Group’s R&D centres and business operation in the United State (“U.S.”). Prior to joining the Group, Dr. WANG worked at Merck Co., Inc. in the U.S. for 20 years where he held senior positions including director of pharmaceutical R&D and director of business development and operation. Dr. WANG holds a bachelor’s degree in science (chemistry) and a master’s degree in science (chemistry) from Nankai University in China, a master’s degree in science (polymer science) and a doctorate in chemistry from University of Connecticut in the U.S. and a MBA degree from Temple University in the U.S.. Dr. WANG has entered into a service contract with the Company for a period of three years commencing from 20 August 2018 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Dr. WANG is entitled to receive a monthly salary of HK$150,000 and an annual director’s fee of HK$60,000. In addition, he is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having given consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

Wang Zhenguo

Mr. Wang Zhenguo is Executive Director of the Company, He was appointed as an executive director of the Company in 2012. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in chemistry from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

Cuilong Zhang

Mr. Zhang Cuilong is Executive Director of the Company. He joined a member of the Group in 1996 and is currently a president of the oncology drug business division of the Group. Mr. ZHANG holds a bachelor’s degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has more than 25 years of technical, marketing and management experience in the pharmaceutical industry. Mr. ZHANG has entered into a service contract with the Company for a period of three years commencing from 9 July 2018 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. ZHANG is entitled to receive a monthly salary of RMB57,750 and an annual director’s fee of HK$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having given consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

李 嘉士

Mr. Lee Ka Sze is Company Secretary, Non-Executive Director of the Company. He was appointed as a non-executive director in 1996, re-designated as an independent nonexecutive director in 1998 and further re-designated as a non-executive director in 2004. Mr. Lee is also a member of the Audit Committee and Remuneration Committee and the Company Secretary of the Company. Mr. Lee holds a bachelor of laws degree from The University of Hong Kong. Mr. Lee is a practising solicitor and a partner of Woo, Kwan, Lee & Lo. Mr. Lee is also a non-executive director of Hopewell Holdings Limited, Yugang International Limited, Safety Godown Company Limited and Termbray Industries International (Holdings) Limited and an independent non-executive director of KWG Property Holding Limited, Esprit Holdings Limited and China Pacific Insurance (Group) Co., Ltd.. All of the above companies are listed on the Stock Exchange of Hong Kong Limited. Mr. Lee is currently a member of the SFC (HKEC Listing) Committee and convenor cum member of the Financial Reporting Review Panel of the Financial Reporting Council.

Chan Siu Keung

Mr. Chan Siu Keung is Independent Non-Executive Director of the Company. He was appointed as an independent non-executive director of the Company in 2004. Mr. Chan is also the chairman of the Audit Committee and Remuneration Committee and a member of the Nomination Committee of the Company. Mr. Chan is a qualified accountant and a member of the Institute of Chartered Accountants of Ontario. Mr. Chan holds a master of business administration degree from York University, Ontario, Canada and has extensive experience in finance and investment.

Chen Chuan

Mr. Chen Chuan is Independent Non-Executive Director of the Company. Mr. Chen holds a bachelor’s degree in Medicine from Norman Bethune University of Medical Science and a Master’s degree in Science from Albert Einstein College of Medicine at Yeshiva University. Mr. Chen is also a director of Beijing Dong Fang Ming Kang Medical Equipment Co., Ltd. (quoted on the National Equities Exchange and Quotations System) and an independent director of Jiangsu Wuzhong Industrial Co., Ltd. (listed on Shanghai Stock Exchange).

Lo Yuk Lam

Prof. Lo Yuk Lam is Independent Non-Executive Director of the Company since 2014. Mr. Lo was appointed as an independent non-executive director of the Company in 2014. Mr. Lo is currently the President of Saitai Biotechnology Research Institute, Vice-Chairman of Santai Eco Fishery Limited, Chairman of Lo & Associates Limited, Senior Director of Questmark Asia Limited and Senior Advisor of Questmark Capital Management Sdn. Bhd.. Mr. Lo is also involved in public services, currently serving as Chairman of the Advisory Council on Food and Environmental Hygiene of the Food and Health Bureau of the HKSAR, a member of the Advisory Committee of the Vocational Training Council, a general committee member of The Chinese Manufacturers’ Association of Hong Kong (“CMA”), Chairman of the Innovation and Technology Committee of the CMA and a consultant of the Chinese Centre for Disease Control and Prevention. Mr. Lo is also an Adjunct Professor of The Chinese University of Hong Kong, a Fellow of The Hong Kong University of Science and Technology and an Honorary Professor of several universities in China. Mr. Lo holds a bachelor’s degree in science from the University of Waterloo and an honorary doctorate of philosophy science from York University in the U.S.. Mr. Lo is also an independent director of Sinovac Biotech Limited (listed on NASDAQ) and an independent nonexecutive director of Luye Pharma Group Ltd. (listed on The Stock Exchange of Hong Kong Limited).

王 波

Mr. Wang Bo is Independent Non-Executive Director of CSPC Pharmaceutical Group Limited. Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd.. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the vicechairman of Chinese Pharmaceutical Enterprises Association and China National Association of Pharmaceutical and Medical Equipment Technical Market. Medical Equipment Technical Market. Mr. Wang is also an independent director of Hainan Shuangcheng Pharmaceutical Co., Ltd. (listed on Shenzhen Stock Exchange), Guangxi Linzhou Pharmaceutical Co., Ltd. (listed on Shanghai Stock Exchange) and Henan Taloph Pharmaceutical Stock Co., Ltd. (listed on Shanghai Stock Exchange). Mr. Wang was also appointed as independent director of Jiuzhitang Co., Ltd. (listed on Shenzhen Stock Exchange) on 12 May 2016. Mr. Wang retired as an independent director of Jiangxu Wuzhong Industrial Co., Ltd. (listed on Shanghai Stock Exchange) on 5 April 2016.

于 金明

Mr. Yu Jinming is Independent Non-Executive Director of the Company. Mr. Yu is an Academician of Chinese Academy of Engineering, and is currently the Honorary President of Shandong Academy of Medical Sciences and the President of Shandong Cancer Hospital. Mr. Yu holds a bachelor’s degree in medicine from Changwei Medical College and a doctorate in radiology from Shandong University.

薪酬

姓名 年薪

Cai Dongchen

13,328,000
更新时间  2017年 12月 31日 星期日 08:00 BJT

期权

姓名 期权 价值

Cai Dongchen

0 0